Allergan
Allergan R&D Chief named as Chairman of Exscientia’s Board of Directors
October 8, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Exscientia, appointment
Artificial intelligence-driven drug discovery firm Exscientia has named industry veteran Dr David Nicholson, current Executive Vice President and Chief R&D …
FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns
June 29, 2020Sales and Marketing AbbVie, Allergan, FDA, pharma
The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, Abicipar pegol, as treatment for …
$63bn Allergan/AbbVie merger review could be delayed by coronavirus
March 18, 2020Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, merger, pharma
The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles on the road to regulatory …
Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine
December 5, 2019Research and Development Allergan, FDA, pharma, ubrogepant
New Phase 3 data has been released showing that both 50mg and 100mg doses of Allergan’s ubrogepant met their primary …
Allergan’s acute migraine therapy ubrogepant shows strength at Phase 3
November 20, 2019Research and Development Allergan, pharma, ubrogepant
Allergan has revealed positive Phase 3 data on its oral calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, illustrating the therapy’s …
Top Ten most popular articles on Pharmafile.com this week
June 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, Bristol-Myers Squibb, China, GSK, Novartis, Takeda, brexit
This week was diverse as always in terms of news coming out of the pharma industry, but the biggest news …
AbbVie poised to acquire Allergan for $63 billion
June 26, 2019Research and Development, Sales and Marketing AbbVie, Allergan, acqusition, pharma
The industry has been rocked with the announcement of another pharmaceutical mega-merger, as it emerged that AbbVie had sealed an …
Allergan shareholders reject proposal to split roles of chairman and CEO
May 2, 2019Research and Development Allergan, Appaloosa, CEO, board of directors, hedge fund, pharma
Allergan shareholders have rejected a proposal to immediately separate the roles of CEO and chairman, both of which are currently …
FDA approves first paediatric treatment for intra-abdominal and urinary tract infections in over 10 years
March 19, 2019Manufacturing and Production, Sales and Marketing Allergan, Avycaz, FDA, pharma
Allergan has revealed that Avycaz (ceftazidime and avibactam) has been awarded an expansion of its label by the FDA to include …
Allergan’s depression drug rapastinel fails to outperform placebo at Phase 3
March 7, 2019Research and Development Allergan, FDA, depression, major depressive disorder, pharma, rapastinel
As Janssen celebrated the FDA approval of the first novel therapy for depression in three decades with Spravato, Allergan released …
Allergan and St Regis Mohawk Tribe take patent ruling to Supreme Court
January 28, 2019Sales and Marketing Allergan, Mohawk, Restasis, St Regis, eye drops, patents
Allergan and the St Regis Mohawk Tribe have asked the Supreme Court to defend a 2017 patent agreement which would …
Allergan strengthens Finance Leadership Team with two appointments
December 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, MIT, Regeneron, appointment, pharma
The Dublin-headquartered multinational Allergan has appointed two experienced pharma investors to its Finance Leadership Team. The biopharmaceutical firm yesterday announced …
Allergan acquires neurotoxin specialist Bonti in $195m deal
September 17, 2018Sales and Marketing Allergan, Bonti, Botox, Neurotoxin, acquisition, deal
The Dublin-headquartered multinational Allergan have agreed to acquire the clinical stage biotech Bonti in a deal worth more than $195 …
FDA refuses Allergan’s uterine bleeding therapy with a request for more data
August 22, 2018Research and Development, Sales and Marketing Allergan, Esmya, FDA, pharma
Allergan has shared the news that the FDA has refused to award marketing authorisation to its ulipristal acetate product Esmya …
Top Ten most popular articles on Pharmafile.com this week
August 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ADHD, Allergan, MHRA, UK, brexit, iraq, pharma, top 10
There was some clarity on Brexit this week as the MHRA set out a plan for the implantation period set …
Latest content
FibroFind appoints Lee Borthwick as CEO
